Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals
Executive Summary
Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.
You may also be interested in...
Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.
How To Get A ‘Great Britain’ Drug Approval In 2021
So much will change on the regulatory front next year that the UK drug regulator, the MHRA, has had to issue dozens of new guidance documents to help pharma and biotech firms navigate the new requirements and assessment routes. A key consideration is how the UK will handle centralized EU applications that are still pending on 31 December.
US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: